Clinical Trials

Texas Children's Cancer Center and Hematology Service has more than 260 clinical trials underway to determine the safety and effectiveness of drug treatments in children. Our Drug Development and Pharmacology Program has developed a number of new anti-cancer agents currently undergoing clinical trials within Texas Children's Cancer Center and Hematology Service which means our patients have access to the newest and most advanced therapies. Approximately, 80% of our patients are involved in clinical trials.

* Designates a "new agent" clinical trial


*ADVL 0222: Phase II Trial of Campath-1H with ALL in 2nd or Refractory Relapse

*ADVL 0319: A Phase 1 Study of CC-5013 in Solid Tumors and Multiple Myeloma

*ADVL 0411: Phase I Trial of Temozolomide in Children with Refractory/Recurrent Leukemia

*ADVL 0413: Phase I Study of The Raf Kinase Inhibitor, Sorafenib in Solid Tumors- Part A

*ADVL 0414: Phase I Trial of Temozolomide, Irinotecan and Vincristine

*ADVL0416: A Phase 1 Study of SAHA in Refractory Solid Tumors or Lymphomas

*ADVL 0419: Phase I Trial of Valproic Acid

*ADVL 0421: Phase II Oxaliplatin

*ADVL04P2: Phase I/II Trial of Epratuzamab for Relapsed CD-22(+) ALL

*ADVL 0516: Phase 1 Trial of BMS-354825 (Dasatinib)

H 14343: Silent Infarct Transfusion (SIT) Trial

H-16530: ASSERT Trial

H-18601: An Open-label, Parallel Group, Pilot Study to Evaluate the Pharmakokinetics, Pharmacodynamics, and Tolerability of ICA-17043 in Pediatric Subjects with Sickle Cell Disease

H-18936: Stroke with Tranfusions Changing to Hydroxyurea (SWITCH)

*NANT 2001-02: Phase I Study of CEP-701

*NANT 2003-01: Phase I Study of Oral Irinotecan, Temozolomide, and Cefixime

*NANT 2004-01 Phase I Trial of Zometa with Cyclophosphamide

*NANT 2004-04: Phase I Study of Fenretinide Lym-X-SorbTM (LX) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma

*PBTC 007: Phase II Trial of ZD1839 and XRT in Newly Diagnosed Brainstem Gliomas

*PBTC 014: Phase I/II Trial of R115777 and XRT in Newly Diagnosed Brainstem Gliomas

*PBTC 016: Phase I/II Trial of Lapatinib

*PBTC 017: Phase I Trial of Cloretazine

*PBTC 018: Phase I Trial of CC-5013 (Lenalidomide)

*PBTC 019: Phase I and Pharmacokinetic Optimal Dosing of Intrathecal Topotecan

*PBTC 020: Phase I of AZD2171

*PBTC 021: Phase I Trial of Capecitabine and XRT in Newly Diagnosed Brainstem Gliomas

*PBTC 022: Phase II Trial of Bevacizumab plus Irinotecan in Recurrent/Progressive or Refractory Malignant Gliomas and Diffuse/Intrinsic Brainstem Gliomas


Page modified on May 11, 2022